NFA
BMRN icon

Nationwide Fund Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Nationwide Fund Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-4,000
Closed -$372K – 286
2017
Q3 		$372K Sell
4,000
-26,800
-87% -$2.37M ﹤0.01% 2324
2017
Q2 		$2.8M Hold
30,800
– – 0.01% 1283
2017
Q1 		$2.7M Buy
30,800
+1,000
+3% +$89K 0.01% 1273
2016
Q4 		$2.47M Sell
29,800
-32,500
-52% -$2.79M 0.01% 1317
2016
Q3 		$5.76M Buy
62,300
+300
+0.5% +$28.3K 0.02% 897
2016
Q2 		$4.82M Buy
62,000
+30,000
+94% +$2.55M 0.02% 958
2016
Q1 		$2.64M Sell
32,000
-40,177
-56% -$3.27M 0.01% 1224
2015
Q4 		$7.56M Sell
72,177
-68,813
-49% -$7.19M 0.03% 710
2015
Q3 		$14.8M Sell
140,990
-34,968
-20% -$4.67M 0.07% 365
2015
Q2 		$24.1M Buy
175,958
+9,440
+6% +$1.17M 0.1% 232
2015
Q1 		$20.8M Sell
166,518
-54,920
-25% -$5.82M 0.08% 291
2014
Q4 		$20M Sell
221,438
-26,510
-11% -$2.2M 0.09% 290
2014
Q3 		$17.9M Buy
247,948
+82,000
+49% +$5.39M 0.08% 318
2014
Q2 		$10.3M Sell
165,948
-62,740
-27% -$3.79M 0.04% 558
2014
Q1 		$15.6M Buy
228,688
+92,540
+68% +$6.82M 0.07% 344
2013
Q4 		$9.57M Buy
136,148
+27,496
+25% +$1.87M 0.04% 591
2013
Q3 		$7.85M Sell
108,652
-18,700
-15% -$1.24M 0.04% 655
2013
Q2 		$7.11M Buy
+127,352
New +$7.94M 0.04% 632

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nationwide Fund Advisors's BMRN Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2017, closing a stake of 4,000 shares — an estimated $372K sold.

Nationwide Fund Advisors first reported a position in BMRN in Q2 2013 and held it in 18 quarters. The position peaked at $24.1M in Q2 2015. 438 funds tracked by Wall St. Rank hold BMRN as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining BioMarin Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 4,000 BioMarin Pharmaceuticals shares in Q4 2017, an estimated $372K.
  • Nationwide Fund Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 18 quarters.
  • Nationwide Fund Advisors's BioMarin Pharmaceuticals position peaked at $24.1M in Q2 2015.
  • 438 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.